Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)Ciara Louise Freeman, Krina K. Patel, Julia Piasecki et al.|Blood|2025Cited by 1
POSTER: MM-1157 Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple MyelomaKrina Patel, Ciara L. Freeman, Susan Bal et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
MM-1157: Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple MyelomaKrina Patel, Ciara L. Freeman, Sarah Larson et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
Trial in Progress: QUINTESSENTIAL—A Phase 2 Study of Arlocabtagene Autoleucel (arlo-cel) in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma (RRMM)Krina Patel, Ciara L. Freeman, Sarah Larson et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0